Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRADLEY D TORPHY

Allopathic & Osteopathic Physicians Family Medicine

NPI
1104052372
CMS profile
276700
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$149,170.66

269 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $118,992.16 146
Lundbeck LLC $15,272.97 16
IMPEL PHARMACEUTICALS INC. $7,071.60 17
PFIZER INC. $6,184.80 34
Ipsen Innovation $515.00 4
Lilly USA, LLC $387.22 18
Teva Pharmaceuticals USA, Inc. $353.08 17
UPSHER-SMITH LABORATORIES LLC $197.46 9
Merck Sharp & Dohme LLC $104.95 5
Amgen Inc. $91.42 3

Page 3 of 6; records 101–150 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRADLEY D TORPHY

NPI 1104052372 · CMS profile ID 276700

Allopathic & Osteopathic Physicians / Family Medicine

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104052372?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRADLEY D TORPHY, NPI 1104052372, CMS profile ID 276700. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104052372?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BRADLEY D TORPHY, NPI 1104052372, CMS profile ID 276700. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104052372?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BRADLEY D TORPHY, NPI 1104052372, CMS profile ID 276700, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 269 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1104052372?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

269 matching records · $149,170.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 269 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 269.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $5.2808/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280435 CMS
AbbVie Inc. $13.1708/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280403 CMS
AbbVie Inc. $9.6308/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280407 CMS
AbbVie Inc. $18.5508/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280411 CMS
AbbVie Inc. $144.6608/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280415 CMS
AbbVie Inc. $479.8008/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280419 CMS
AbbVie Inc. $119.7008/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280423 CMS
AbbVie Inc. $48.0008/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280427 CMS
Teva Pharmaceuticals USA, Inc. $2.9208/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056743073 CMS
Teva Pharmaceuticals USA, Inc. $28.2208/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056743081 CMS
AbbVie Inc. $120.9608/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280399 CMS
AbbVie Inc. $15.9508/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280395 CMS
PFIZER INC. $6.0208/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050494829 CMS
Lilly USA, LLC $27.6608/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031275659 CMS
IMPEL PHARMACEUTICALS INC. $18.7908/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989359513 CMS
IMPEL PHARMACEUTICALS INC. $3.4508/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989359507 CMS
Teva Pharmaceuticals USA, Inc. $10.4608/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056743077 CMS
PFIZER INC. $16.7108/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050660177 CMS
IMPEL PHARMACEUTICALS INC. $17.7408/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989359503 CMS
AbbVie Inc. $25.0108/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280391 CMS
Merck Sharp & Dohme LLC $15.8508/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048668177 CMS
AbbVie Inc. $2,875.0008/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280387 CMS
AbbVie Inc. $10.4908/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280383 CMS
Lilly USA, LLC $20.0308/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031284391 CMS
AbbVie Inc. $525.0007/25/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280379 CMS
PFIZER INC. $26.3707/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050491959 CMS
Lilly USA, LLC $26.1407/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031292197 CMS
AbbVie Inc. $24.4407/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280375 CMS
AbbVie Inc. $34.3807/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280367 CMS
AbbVie Inc. $2,875.0007/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280371 CMS
Teva Pharmaceuticals USA, Inc. $17.0107/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056743027 CMS
AbbVie Inc. $17.2407/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280363 CMS
PFIZER INC. $15.8607/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049514459 CMS
PFIZER INC. $2.6307/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050552785 CMS
AbbVie Inc. $4,025.0007/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280351 CMS
AbbVie Inc. $2,875.0007/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280355 CMS
AbbVie Inc. $4,025.0007/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280359 CMS
Merck Sharp & Dohme LLC $16.8607/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048668189 CMS
PFIZER INC. $6.4606/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049488953 CMS
PFIZER INC. $3.1206/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050348375 CMS
Lilly USA, LLC $20.7806/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031291741 CMS
AbbVie Inc. $262.5006/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280347 CMS
Teva Pharmaceuticals USA, Inc. $31.7806/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056743017 CMS
AbbVie Inc. $16.4406/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280343 CMS
PFIZER INC. $26.4506/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049110261 CMS
AbbVie Inc. $124.9906/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280333 CMS
AbbVie Inc. $10.8006/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280339 CMS
AbbVie Inc. $23.7306/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280309 CMS
AbbVie Inc. $88.8706/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280314 CMS
AbbVie Inc. $124.1606/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999280317 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $173,037.31 392
PY2020 $202,156.61 297
PY2021 $216,340.86 343
PY2022 $244,447.98 400
PY2023 $149,170.66 269
PY2024 $156,111.58 242
PY2025 $206,380.85 237

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $289,032.38 72
PY2024 Principal investigator $330,869.19 96
PY2023 Recipient $9,884.25 3
PY2023 Principal investigator $877,779.33 37
PY2022 Recipient $1,319.00 3
PY2022 Principal investigator $92,733.31 21
PY2021 Recipient $13,125.00 1
PY2021 Principal investigator $32,481.42 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

72 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH INSTITUTE LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202532759
Principal investigator 1 Amgen Inc. $6,300.00 12/24/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH INSTITUTE LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]) No dispute reported 06/30/2026 1246640205
Principal investigator 1 H. Lundbeck A S $2,684.00 12/01/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777923
Principal investigator 1 PFIZER INC. $9,526.85 11/20/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228729160
Principal investigator 1 ABBVIE INC. $324.68 11/04/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202520313
Principal investigator 1 ABBVIE INC. $533.26 11/04/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH INSTITUTE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202520315
Principal investigator 1 Ipsen Innovation $77.81 10/27/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292062
Principal investigator 1 Ipsen Innovation $2,449.40 10/27/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292064
Principal investigator 1 ABBVIE INC. $651.92 10/09/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202514587
Principal investigator 1 ABBVIE INC. $8,000.00 09/25/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202512270
Principal investigator 1 ABBVIE INC. $6,000.00 09/25/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH INSTITUTE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202512272
Principal investigator 1 H. Lundbeck A S $494.00 09/10/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774546
Principal investigator 1 ABBVIE INC. $3,350.88 09/03/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH INSTITUTE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202507415
Principal investigator 1 Ipsen Innovation $77.81 08/28/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292060
Principal investigator 1 H. Lundbeck A S $3,314.00 08/07/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251773391
Principal investigator 1 H. Lundbeck A S $2,244.00 08/07/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251773394
Principal investigator 1 ABBVIE INC. $384.02 08/05/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH INSTITUTE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202501660
Principal investigator 1 Ipsen Innovation $180.00 07/31/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292054
Principal investigator 1 Ipsen Innovation $300.00 07/31/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292056
Principal investigator 1 Ipsen Innovation $300.00 07/31/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292058
Principal investigator 1 Ipsen Innovation $450.00 07/29/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292052
Principal investigator 1 H. Lundbeck A S $2,500.00 07/18/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251772711
Principal investigator 1 H. Lundbeck A S $3,000.00 07/18/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251772715
Principal investigator 1 H. Lundbeck A S $3,125.00 07/18/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251772720
Principal investigator 1 H. Lundbeck A S $10,108.00 07/18/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251772724
Principal investigator 1 H. Lundbeck A S $2,600.00 07/18/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251772728
Principal investigator 1 ABBVIE INC. $2,433.60 07/02/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH INSTITUTE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202494459
Principal investigator 1 Ipsen Innovation $1,584.64 06/30/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292040
Principal investigator 1 Ipsen Innovation $77.81 06/30/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292042
Principal investigator 1 Ipsen Innovation $77.81 06/30/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292044
Principal investigator 1 Ipsen Innovation $969.80 06/30/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292046
Principal investigator 1 Ipsen Innovation $969.80 06/30/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292048
Principal investigator 1 Ipsen Innovation $1,584.64 06/30/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292050
Principal investigator 1 PFIZER INC. $3,835.35 06/13/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228776322
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $16,177.97 06/10/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE LLC
A Real-World Retrospective Chart Review to Evaluate Effectiveness and Safety of Fremanezumab in Migraine Patients with a Body Mass index No dispute reported 06/30/2026 1244052779
Principal investigator 1 ABBVIE INC. $42,489.50 06/05/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER &
IIT-2020-11028//Ubrelvy Efficacy and Safety in the Treatment of Acute Migraine in Patients Currently Treated with CGRP monoclonal antibodies (CGRPmAbs)(A23-256) No dispute reported 06/30/2026 1202490503
Principal investigator 1 ABBVIE INC. $1,066.52 06/03/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH INSTITUTE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202488863
Principal investigator 1 Ipsen Innovation $150.00 05/30/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292036
Principal investigator 1 Ipsen Innovation $90.00 05/30/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292038
Principal investigator 1 ABBVIE INC. $2,637.70 05/06/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH INSTITUTE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202481397
Principal investigator 1 Ipsen Innovation $1,569.56 04/28/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292016
Principal investigator 1 Ipsen Innovation $1,569.56 04/28/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292018
Principal investigator 1 Ipsen Innovation $969.80 04/28/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292020
Principal investigator 1 Ipsen Innovation $969.80 04/28/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292028
Principal investigator 1 Ipsen Innovation $969.80 04/28/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292030
Principal investigator 1 Ipsen Innovation $77.81 04/28/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292032
Principal investigator 1 PFIZER INC. $5,218.20 04/24/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228762709
Principal investigator 1 Ipsen Innovation $300.00 04/23/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292022
Principal investigator 1 Ipsen Innovation $180.00 04/23/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292024
Principal investigator 1 ABBVIE INC. $1,066.52 04/03/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH INSTITUTE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202473594
Principal investigator 1 Ipsen Innovation $6,772.50 04/03/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292012
Principal investigator 1 Ipsen Innovation $2,000.00 04/03/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292014
Principal investigator 1 Ipsen Innovation $1,693.00 04/03/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292026
Principal investigator 1 Ipsen Innovation $1,050.00 04/03/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292034
Principal investigator 1 Eli Lilly and Company $34,037.00 03/11/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187879143
Principal investigator 1 ABBVIE INC. $6,136.26 03/07/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH INSTITUTE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202459825
Principal investigator 1 H. Lundbeck A S $370.36 03/05/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768210
Principal investigator 1 H. Lundbeck A S $238.89 03/05/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768213
Principal investigator 1 H. Lundbeck A S $123.64 03/05/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768217
Principal investigator 1 H. Lundbeck A S $26.05 03/05/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768222
Principal investigator 1 H. Lundbeck A S $25.00 03/05/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768227
Principal investigator 1 H. Lundbeck A S $126.60 03/05/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768231
Principal investigator 1 Ipsen Innovation $150.00 03/04/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292008
Principal investigator 1 Ipsen Innovation $180.00 03/04/2025 Non-covered Recipient Entity
Chicago Headache Center And Research Institute
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292010
Principal investigator 1 Amgen Inc. $7,585.44 02/10/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH INSTITUTE LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) No dispute reported 06/30/2026 1246640207
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $32,356.02 02/10/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE LLC
A Real-World Retrospective Chart Review to Evaluate Effectiveness and Safety of Fremanezumab in Migraine Patients with a Body Mass index No dispute reported 06/30/2026 1244052777
Principal investigator 1 H. Lundbeck A S $386.69 02/04/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251766916
Principal investigator 1 Eli Lilly and Company $1,411.44 01/31/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187878089
Principal investigator 1 PFIZER INC. $14,005.80 01/23/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER AND RESEARCH INSTITUTE LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228767939
Principal investigator 1 Eli Lilly and Company $21,751.00 01/21/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187883300
Principal investigator 1 Eli Lilly and Company $621.61 01/15/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187878843
Principal investigator 1 ABBVIE INC. $533.26 01/02/2025 Non-covered Recipient Entity
CHICAGO HEADACHE CENTER & RESEARCH INSTITUTE LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202435070